Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA
Sign Up to like & getrecommendations! Published in 2021 at "ESMO Open"
DOI: 10.1016/j.esmoop.2020.100041
Abstract: On 10 December 2020 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended granting a conditional marketing authorisation for selpercatinib (Retevmo) for the treatment of cancers that display… read more here.
Keywords: rethinking treatment; ret; treatment ret; thyroid ... See more keywords